Segment Information - Schedule of Financial Information by Segment (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Segment Reporting Information [Line Items]
Net sales	$ 2,938		$ 3,776	$ 6,873	$ 9,711
Gross profit	2,136		597	4,068	2,506
Direct expenses	21,683		41,877	76,353	78,445
Segment contribution	(19,547)		(41,280)	(72,285)	(75,939)
Indirect expenses	22,929		(45,455)	34,061	(38,500)
Income (loss) from operations	(42,476)		4,175	(106,346)	(37,439)
Components of other
Change in fair value of contingent consideration liability	(85,407)		(45,047)	(104,339)	(40,198)
Change in fair value of contingent stock consideration				(120)	611
Goodwill impairment	0	$ 29,633	0	29,633	0
IPR&D impairment	107,800		0	107,800	0
Cell Therapy
Segment Reporting Information [Line Items]
Direct expenses	8,456		24,820	48,618	46,033
Segment contribution	(8,456)		(24,820)	(48,618)	(46,033)
Components of other
Goodwill impairment				29,633
Biobanking
Segment Reporting Information [Line Items]
Net sales	1,278		1,373	2,635	2,656
Gross profit	793		108	1,678	443
Direct expenses	86		256	430	882
Segment contribution	707		(148)	1,248	(439)
Degenerative Disease
Segment Reporting Information [Line Items]
Net sales	1,660		2,403	4,238	7,055
Gross profit	1,343		489	2,390	2,063
Direct expenses	1,889		3,179	4,898	4,638
Segment contribution	(546)		(2,690)	(2,508)	(2,575)
Other
Segment Reporting Information [Line Items]
Direct expenses	11,252		13,622	22,407	26,892
Segment contribution	(11,252)		(13,622)	(22,407)	(26,892)
Indirect expenses	22,929		(45,455)	34,061	(38,500)
Components of other
Change in fair value of contingent consideration liability	(85,407)		(45,047)	(104,339)	(40,198)
Change in fair value of contingent stock consideration	(10)		(954)	(120)	611
Goodwill impairment				29,633
IPR&D impairment	107,800			107,800
Amortization	546		546	1,087	1,087
Total other	$ 22,929		$ (45,455)	$ 34,061	$ (38,500)